

<b>Reference:</b>	FOI.7705.22
<b>Subject:</b>	Saxenda medication
<b>Date of Request:</b>	14 December 2021

**Requested:**

1. What steps has your CCG/Trust taken to ensure compliance with the mandatory NICE tag 664 for Saxenda. If none, what plans are in place to address this?
2. Have patients that are eligible to utilise the NICE approved product Saxenda been able to access this product? If so please provide the volume, or if not, please provide any current plans to address this.

**Response:**

1. Hywel Dda University Health Board (UHB) confirms that potential demand and capacity was reviewed in the context of existing services and the prescribing pathways stipulated in the NICE tag with a Situation Background Assessment Recommendation (SBAR) being developed and taken to the Effective Clinical Practice Advisory Panel. Following this, a working group has been set up to monitor the demand for Saxenda and the impact on existing service pathways.
2. The UHB confirms that eligible patients have been able to access Saxenda medication via the Level 3 Specialist Multi-Disciplinary Weight Management clinic, with 25 people being prescribed Saxenda.